One of the most lucrative professions these days is to be a cosmetic surgeon. But for those of us who don't fancy biology lab courses or surgery training, there is another way to cash in on the growing cosmetic surgery craze. As just one example, the lucky people who bought ten thousand dollars worth of Allergran in 1990 are now sitting on a cash pile of $160,000.

Allegran (NYSE: AGN) is the California-based company that sells Botox to cosmetic surgeons. Another of their hit products is the Restatis eye-drop treatment and the FDA recently approved silicone breast implants which will likely be very popular for them starting in 2007.

Allegran released their latest quarterly report today and the future appears rosy. Sales of Botox was up 20% just since the last quarter. In 2007 they expect sales of about $3.5 billion and Botox will represent about $1.1 billion of this total, their breast implant products will account for about $250 million and their dermal filler products (including JUVEDERM) will account for sales of about $120 million.

A lot of the future potential has already been priced into the stock. And if there are any health/medical scares about the products, the comapny stock could plummet very quickly. So get professional advice if you are not an expert in this sector, but if you know something about the insides of what is going on in the cosmetic surgery industry, it may be worthwhile to put some money into two or three of the up and coming cosmetic surgery companies where you've heard and seen they are the best in their field and where demand for their product is growing astronomically.